Changing Crohn's disease management: Need for new goals and indices to prevent disability and improve quality of life

Journal of Crohn's and Colitis

Volumn 6, Issue SUPPL.2, 2012, Pages

  Hommes, Daniel ^a   Colombel, Jean Frédéric ^b   Emery, Paul ^c   Greco, Marco ^d   Sandborn, William J ^e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIV LILLE   (France)

^c UNIVERSITY OF LEEDS   (United Kingdom)

^d European Federation of Crohn's and Ulcerative Colitis Associations   (Belgium)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Crohn's disease; Deep remission; Disability index; IMPACT survey; L mann damage; Management; Quality of life; Score; Treat to target approach

Indexed keywords

ADALIMUMAB; INFLIXIMAB; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ARTICLE; COST CONTROL; CROHN DISEASE; DISABILITY; DISABILITY SEVERITY; DISEASE ACTIVITY; DOCTOR PATIENT RELATION; ENDOSCOPY; FATIGUE; HEALTH CARE COST; HEALTH CARE DELIVERY; HEALTH CARE PERSONNEL; HEALTH CARE QUALITY; HEALTH CARE UTILIZATION; HOSPITALIZATION; HUMAN; NURSE PATIENT RELATIONSHIP; PATIENT SATISFACTION; PRIORITY JOURNAL; QUALITY OF LIFE; REMISSION; RHEUMATOID ARTHRITIS; ULCERATIVE COLITIS;

ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; ATTITUDE TO HEALTH; CROHN DISEASE; DISEASE PROGRESSION; HEALTH SURVEYS; HUMANS; PATIENT CARE PLANNING; QUALITY OF LIFE; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84859059470     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1016/S1873-9946(12)60502-9     Document Type: Article

References (61)

1. Cosnes J, Cattan S, Blain A, Beaugerie L, Carbonnel F, Parc R, Gendre JP Long-term evolution of disease behavior of Crohn's disease. Inflamm Bowel Dis 2002, 8:244-250.
2. Thia KT, Sandborn WJ, Harmsen WS, Zinsmeister AR, Loftus EV Risk factors associated with progression to intestinal complications of Crohn's disease in a population-based cohort. Gastroenterology 2010, 139:114-155.
3. Munkholm P, Langholz E, Davidsen M, Binder V Disease activity courses in a regional cohort of Crohn's disease patients. Scand J Gastroenterol 1995, 30:699-706.
4. Duricova D, Pedersen N, Elkjaer M, Gamborg M, Munkholm P, Jess T Overall and cause-specific mortality in Crohn's disease: a meta-analysis of population-based studies. Inflamm Bowel Dis 2010, 16:347-353.
5. Bernklev T, Jahnsen J, Lygren I, Henriksen M, Vatn M, Moum B Health-related quality of life in patients with inflammatory bowel disease measured with the short form-36: psychometric assessments and a comparison with general population norms. Inflamm Bowel Dis 2005, 11:909-918.
6. Stjernman H, Tysk C, Almer S, Ström M, Hjortswang H Unfavourable outcome for women in a study of health-related quality of life, social factors and work disability in Crohn's disease. Eur J Gastroenterol Hepatol 2011, 23:671-679.
7. Ghosh S, Mitchell R Impact of inflammatory bowel disease on quality of life: Results of the European Federation of Crohn's and Ulcerative Colitis Associations (EFCCA) patient survey. J Crohns Colitis 2007, 1:10-20.
8. Peyrin-Biroulet L, Cieza A, Sandborn WJ, Kostanjsek N, Kamm MA, Hibi T, Lémann M, Stucki G, Colombel JF Disability in inflammatory bowel diseases: developing ICF Core Sets for patients with inflammatory bowel diseases based on the International Classification of Functioning, Disability, and Health. Inflamm Bowel Dis 2010, 16:15-22.
9. Wilson B, Greco M, Hommes DW, Vermeire S, Bell C, Avedano L. A European Crohn's and ulcerative colitis patient life IMPACT survey. Abstract PO875, 19th United European Gastroenterology Week, Stockholm, Sweden, October 22-26, 2011.
10. Hoffman C, Rice D, Sung HY Persons with chronic conditions. Their prevalence and costs. JAMA 1996, 276:1473-1479.
11. Yu AP, Cabanilla LA, Wu EQ, Mulani PM, Chao J The costs of Crohn's disease in the United States and other Western countries: a systematic review. Curr Med Res Opin 2008, 24:319-328.
12. Gibson TB, Ng E, Ozminkowski RJ, Wang S, Burton WN, Goetzel RZ, Maclean R The direct and indirect cost burden of Crohn's disease and ulcerative colitis. J Occup Environ Med 2008, 50:1261-1272.
13. Cohen RD, Larson LR, Roth JM, Becker RV, Mummert LL The cost of hospitalization in Crohn's disease. Am J Gastroenterol 2000, 95:30-52.
14. American Hospital Association Patients or paperwork? The regulatory burden facing America's hospitals Accessed 12 January 2012. http://www.aha.org/content/00-10/FinalPaperworkReport.pdf.
15. McGlynn EA, Asch SM, Adams J, Keesey J, Hicks J, DeCristofaro A, Kerr EA The quality of health care delivered to adults in the United States. N Engl J Med 2003, 348:2635-2645.
16. Porter ME What is value in health care?. N Engl J Med 2010, 363:2477-2481.
17. O'Connor AM, Llewellyn-Thomas HA, Flood AB Modifying unwarranted variations in health care: shared decision making using patient decision aids. Health Aff (Millwood) 2004, Suppl Variation:VAR63-72.
18. Bodenheimer T, Lorig K, Holman H, Grumbach K Patient self-management of chronic disease in primary care. JAMA 2002, 288:2469-2475.
19. Elkjaer M, Shuhaibar M, Burisch J, Bailey Y, Scherfig H, Laugesen B, Avnstrøm S, Langholz E, O'Morain C, Lynge E, Munkholm P E-health empowers patients with ulcerative colitis: a randomised controlled trial of the web-guided 'Constant-care' approach. Gut 2010, 59:1652-1661.
20. Chetney R Home care's challenge: move the information ... not the patient. Home Healthc Nurse 2003, 21:712.
21. Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, Lichtiger S, D'Haens G, Diamond RH, Broussard DL, Tang KL, van der Woude CJ, Rutgeerts P, for the SONIC Study Group Infliximab, azathioprine, or combination therapy for Crohn's disease. New Engl J Med 2010, 362:1383-1395.
22. Baert F, Moortgat L, van Assche G, Caenepeel P, Vergauwe P, de Vos M, Stokkers P, Hommes D, Rutgeerts P, Vermeire S, d'Haens G, for the Belgian Inflammatory Bowel Disease Research Group and the North-Holland Gut Club Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease. Gastroenterology 2010, 138:463-468.
23. Louis E, Mary JY, Vernier-Massouille G, Grimaud JC, Bouhnik Y, Laharie D, Dupas JL, Pillant H, Picon L, Veyrac M, Flamant M, Savoye G, Jian R, Devos M, Porcher R, Paintaud G, Piver E, Colombel JF, Lémann M, Groupe D'etudes Thérapeutiques Des Affections Inflammatoires Digestives Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped. Gastroenterology 2012, 142:63-70.
24. Colombel J, Rutgeerts P, Sandborn WJ, Camez A, Pollack PF, Chen N, Yang M, Chao J, Mulani PM. Deep remission for adalimumab-treated patients with moderate to severe ileocolonic Crohn's disease: results from EXTEND. Abstract OP31, 5th Congress of the European Crohn's and Colitis Organisation, Prague, Czech Republic, February 25-27, 2010.
25. Colombel JF, Rutgeerts P, Sandborn WJ, YangM, Lomax KG, Pollack PF, Thakkar R, Camez A, Chen N, Mulani PM, Chao J. Deep remission predicts long-term outcomes for adalimumab-treated patients with Crohn's disease: data from EXTEND. Abstract OP371, 18th United European Gastroenterology Week, Barcelona. Spain, October 23-27, 2010.
26. Colombel J, Sandborn WJ, Louis E, Panaccione R, Yang M, Chao J, Mulani PM. Economic impact of deep remission in adalimumab-treated patients with Crohn's disease: Results from EXTEND. Abstract PO70, 6th Congress of the European Crohn's and Colitis Organisation, Dublin, Ireland, February 24-26, 2011.
27. D'Haens GR, Noman M, Baert F, Hiele M, van Assche G, Daperno M, Rutgeerts P Endoscopic healing after infliximab treatment for Crohn's disease provides a longer time to relapse. Gastroenterology 2002, 122:776(A).
28. Schnitzler F, Fidder H, Ferrante M, Noman M, Arijs I, van Assche G, Hoffman I, van Steen K, Vermeire S, Rutgeerts P Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn's disease. Inflamm Bowel Dis 2009, 15:1295-1301.
29. Bodily KD, Fletcher JG, Solem CA, Johnson CD, Fidler JL, Barlow JM, Bruesewitz MR, McCollough CH, Sandborn WJ, Loftus EV, Harmsen WS, Crownhart BS Crohn Disease: mural attenuation and thickness at contrast-enhanced CT Enterography - correlation with endoscopic and histologic findings of inflammation. Radiology 2006, 238:505-516.
30. Rimola J, Rodriguez S, García-Bosch O, Ordés I, Ayala E, Aceituno M, Pellisé M, Ayuso C, Ricart E, Donoso L, Panés J Magnetic resonance for assessment of disease activity and severity in ileocolonic Crohn's disease. Gut 2009, 58:1113-1120.
31. Lémann M, Colombel J-F, Grimaud JC, et al. Fecal calprotectin and high sensitivity C-reactive protein levels to predict mucosal healing in patients with Crohn's disease. A subanalysis of the STORI study [abstract]. Presented at the 18th United European Gastroenterology Week, Barcelona, October 23-27, 2010.
32. Louis E, Baumgart DC, Ghosh S, Gomollón F, Hanauer S, Hart A, Irving P What changes in inflammatory bowel disease management can be implemented today?. J Crohn's Colitis 2012, 6(Suppl 2):S260-S267.
33. Verstappen SM, Jacobs JW, van der Veen MJ, Heurkens AH, Schenk Y, ter Borg EJ, Blaauw AA, Bijlsma JW, Utrecht Rheumatoid Arthritis Cohort study group Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). Ann Rheum Dis 2007, 66:1443-1449.
34. Grigor C, Capell H, Stirling A, McMahon AD, Lock P, Vallance R, Kincaid W, Porter D Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a singleblind randomised controlled trial. Lancet 2004, 364:263-269.
35. Schoels M, Knevel R, Aletaha D, Bijlsma JWJ, Breedveld FC, Boumpas DT, Burmester G, Combe B, Cutolo M, Dougados M, Emery P, van der Heijde D, Huizinga TW, Kalden J, Keystone EC, Kvien TK, Martin-Mola E, Montecucco C, de Wit M, Smolen JS Evidence for treating rheumatoid arthritis to target: results of a systematic literature search. Ann Rheum Dis 2010, 69:638-643.
36. Abbott. Efficacy and safety of two treatment models in subjects with moderate to severe Crohn's disease (CALM). In: [Internet]. Bethesda (MD): National Library of Medicine (US). 2000-2012. Available from: : . Accessed 24 January 2012. ctgov:NCT01235689.
37. Robarts Research Institute. Trial of a treatment algorithm for the management of Crohn's disease (REACT). In: [Internet]. Bethesda (MD): National Library of Medicine (US). 2000-2012. Available from: : . Accessed 24 January 2012. ctgov:NCT01030809.
38. University of Melbourne. Post-operative Crohn's Endoscopic Recurrence Study (POCER). In: [Internet]. Bethesda (MD): National Library of Medicine (US). 2000-2012. Available from: : . Accessed 24 January 2012. ctgov:NCT00989560.
39. Abbott Laboratories, GETECCU. The ADACAL Study: cAlprotectin and hsCRP as markers of a new Diagnostic-therapeutic strAtegy that assesses muCosal Activity to individuaLize treatment and improve the prognosis of patients with Crohn's disease treated with immunosuppressants. []. Accessed 26 January 2012. http://www.geteccu.org/index.asp?pagina=actividadesgeteccu&subpagina=66&c=16.
40. Sharp JT, Lidsky MD, Collins LC, Moreland J Methods of scoring the progression of radiologic changes in rheumatoid arthritis. Correlation of radiologic, clinical and laboratory abnormalities. Arthritis Rheum 1971, 14:706-720.
41. van der Heijde DM, van Leeuwen MA, van Riel PL, van de Putte LB Radiographic progression on radiographs of hands and feet during the first 3 years of rheumatoid arthritis measured according to Sharp's method (van der Heijde modification). J Rheumatol 1995, 22:1792-1796.
42. Pariente B, Cosnes J, Danese S, Sandborn WJ, Lewin M, Fletcher JG, Chowers Y, D'Haens G, Feagan BG, Hibi T, Hommes DW, Irvine EJ, Kamm MA, Loftus EV, Louis E, Michetti P, Munkholm P, Oresland T, Panóes J, Peyrin-Biroulet L, Reinisch W, Sands BE, Schoelmerich J, Schreiber S, Tilg H, Travis S, van Assche G, Vecchi M, Mary JY, Colombel JF, Lémann M Development of the Crohn's disease digestive damage score, the Lémann score. Inflamm Bowel Dis 2011, 17:1415-1422.
43. Kappos L, Freedman MS, Polman CH, Edan G, Hartung HP, Miller DH, Montalbán X, Barkhof F, Radü EW, Bauer L, Dahms S, Lanius V, Pohl C, Sandbrink R, BENEFIT Study Group Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. Lancet 2007, 370:389-397.
44. Bombardier C, Barbieri M, Parthan A, Zack DJ, Walker V, Macarios D, Smolen JS The relationship between joint damage and functional disability in rheumatoid arthritis: a systematic review. Ann Rheum Dis 2011, published online November 29. 10.1136/annrheumdis-2011-200343.
45. World Health Organization International Classification of Functioning, Disability and Health (ICF) 2001, WHO, Geneva, Accessed 24 January 2012. http://www.who.int/classifications/icf/en.
46. Peyrin-Biroulet L, Cieza A, Sandborn WJ, Coenen M, Chowers Y, Hibi T, Kostanjsek N, Stucki G, Colombel JF, the International Programme to Develop New Indexes for Crohn's Disease (IPNIC) group Development of the first disability index for inflammatory bowel disease based on the international classification of functioning, disability and health. Gut 2011, published online June 5. 10.1136/gutjnl-2011-300049.
47. Emery P, Salmon M Early rheumatoid arthritis: Time to aim for remission?. Ann Rheum Dis 1995, 54:944-947.
48. Smolen JS, Aletaha D, Bijlsma JW, Breedveld FC, Boumpas D, Burmester G, Combe B, Cutolo M, de Wit M, Dougados M, Emery P, Gibofsky A, Gomez-Reino JJ, Haraoui B, Kalden J, Keystone EC, Kvien TK, McInnes I, Martin-Mola E, Montecucco C, Schoels M, van der Heijde D, T2T Expert Committee Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010, 69:631-637.
49. Felson DT, Smolen JS, Wells G, Zhang B, van Tuyl LH, Funovits J, Aletaha D, Allaart CF, Bathon J, Bombardieri S, Brooks P, Brown A, Matucci-Cerinic M, Choi H, Combe B, de Wit M, Dougados M, Emery P, Furst D, Gomez-Reino J, Hawker G, Keystone E, Khanna D, Kirwan J, Kvien TK, Landewé R, Listing J, Michaud K, Martin-Mola E, Montie P, Pincus T, Richards P, Siegel JN, Simon LS, Sokka T, Strand V, Tugwell P, Tyndall A, van der Heijde D, Verstappen S, White B, Wolfe F, Zink A, Boers M American College of Rheumatology/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum Dis 2011, 70:13-40.
50. Mulherin D, Fitzgerald O, Bresnihan B Clinical improvement and radiological deterioration in rheumatoid arthritis: evidence that the pathogenesis of synovial inflammation and articular erosion may differ. Br J Rheumatol 1996, 35:1263-1268.
51. Molenaar ET, Voskuyl AE, Dinant HJ, Bezemer PD, Boers M, Dijkmans BA Progression of radiologic damage in patients with rheumatoid arthritis in clinical remission. Arthritis Rheum 2004, 50:36-42.
52. Brown AK, Quinn MA, Karim Z, Conaghan PG, Peterfy CG, Hensor E, Wakefield RJ, O'Connor PJ, Emery P Presence of significant synovitis in rheumatoid arthritis patients with disease-modifying antirheumatic drug-induced clinical remission: evidence from an imaging study may explain structural progression. Arthritis Rheum 2006, 54:3761-3773.
53. Brown AK, Conaghan PG, Karim Z, Quinn MA, Ikeda K, Peterfy CG, Hensor E, Wakefield RJ, O'Connor PJ, Emery P An explanation for the apparent dissociation between clinical remission and continued structural deterioration in rheumatoid arthritis. Arthritis Rheum 2008, 58:2958-2967.
54. Saleem B, Brown AK, Quinn M, Karim Z, Hensor E, Conaghan PG, Peterfy CG, Wakefield R, Emery P. Can flare be predicted in DMARD treated RA patients in remission, and is it important? Ann Rheum Dis In press.
55. Quinn MA, Conaghan PG, O'Connor PJ, Karim Z, Greenstein A, Brown A, Brown C, Fraser A, Jarret S, Emery P Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2005, 52:27-35.
56. Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, van Vollenhoven R, Sharp J, Perez JL, Spencer-Green GT The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006, 54:26-37.
57. Emery P, Genovese MC, van Vollenhoven R, Sharp JT, Patra K, Sasso EH Less radiographic progression with adalimumab plus methotrexate versus methotrexate monotherapy across the spectrum of clinical response in early rheumatoid arthritis. J Rheumatol 2009, 36:1429-1441.
58. Emery P, Breedveld FC, Hall S, Durez P, Chang DJ, Robertson D, Singh A, Pedersen RD, Koenig AS, Freundlich B Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet 2008, 372:375-382.
59. Emery P, Tore K, Combe B, Freundlich B, Robertson D, Ferdousi T, Bananis E, Pedersen R, Koenig A. Combination etanercept and methotrexate provides better disease control in very early (<4 months) versus early rheumatoid arthritis (>4 months and <2 years): post hoc analyses from the COMET study. Ann Rheum Dis In press.
60. Emery P, Smolen JS, Kavanaugh A, van Vollenhoven R, Pavelka K, Durez P, Guerette B, Redden L, Kupper H, Patra K, Fleischmann R Maintenance of biologic-free disease control in early rheumatoid arthritis patients after induction of low disease activity with adalimumab plus methotrexate. Ann Rheum Dis 2011, 70(Suppl):262.
61. Bejarano V, Conaghan PG, Quinn MA, Saleem B, Emery P Benefits 8 years after a remission induction regime with an infliximab and methotrexate combination in early rheumatoid arthritis. Rheumatology (Oxford) 2010, 49:1971-1974.